These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15736963)

  • 1. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.
    Cruchaga C; Odriozola L; Andréola M; Tarrago-Litvak L; Martínez-Irujo JJ
    Biochemistry; 2005 Mar; 44(9):3535-46. PubMed ID: 15736963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
    Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate.
    Odriozola L; Cruchaga C; Andréola M; Dollé V; Nguyen CH; Tarrago-Litvak L; Pérez-Mediavilla A; Martínez-Irujo JJ
    J Biol Chem; 2003 Oct; 278(43):42710-6. PubMed ID: 12917424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.
    Villahermosa ML; Martinez-Irujo JJ; Cabodevilla F; Santiago E
    Biochemistry; 1997 Oct; 36(43):13223-31. PubMed ID: 9341211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
    Maga G; Hübscher U; Pregnolato M; Ubiali D; Gosselin G; Spadari S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1192-200. PubMed ID: 11257034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer.
    Cruchaga C; Anso E; Font M; Martino VS; Rouzaut A; Martinez-Irujo JJ
    Biochem J; 2007 Jul; 405(1):165-71. PubMed ID: 17355225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
    Xia Q; Radzio J; Anderson KS; Sluis-Cremer N
    Protein Sci; 2007 Aug; 16(8):1728-37. PubMed ID: 17656585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.
    Canard B; Sarfati SR; Richardson CC
    J Biol Chem; 1998 Jun; 273(23):14596-604. PubMed ID: 9603976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors.
    Mas A; Vázquez-Alvarez BM; Domingo E; Menéndez-Arias L
    J Mol Biol; 2002 Oct; 323(2):181-97. PubMed ID: 12381314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
    Song Y; Chan JM; Tovian Z; Secrest A; Nagy E; Krysiak K; Bergan K; Parniak MA; Oldfield E
    Bioorg Med Chem; 2008 Oct; 16(19):8959-67. PubMed ID: 18789701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs.
    White EL; Parker WB; Ross LJ; Shannon WM
    Antiviral Res; 1993 Dec; 22(4):295-308. PubMed ID: 7506513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate.
    Cruchaga C; Ansó E; Rouzaut A; Martínez-Irujo JJ
    J Biol Chem; 2006 Sep; 281(38):27744-52. PubMed ID: 16829515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
    Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
    Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
    Gu Z; Quan Y; Li Z; Arts EJ; Wainberg MA
    J Biol Chem; 1995 Dec; 270(52):31046-51. PubMed ID: 8537362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance.
    Vaccaro JA; Anderson KS
    Biochemistry; 1998 Oct; 37(40):14189-94. PubMed ID: 9760256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.